NASDAQ:ARAY

Accuray (ARAY) Stock Forecast, Price & News

$2.72

-0.01 (-0.37%)

(As of 09/29/2023 ET)

Compare

Today's Range: $2.69
▼
$2.76
50-Day Range: $2.63
▼
$4.26
52-Week Range: $1.81
▼
$4.30

Volume: 305,402 shs
Average Volume: 367,733 shs
Market Capitalization: $262.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Accuray MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
6.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.77
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$88,620 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.02) to $0.17 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

748th out of 972 stocks

Surgical & Medical Instruments Industry

80th out of 101 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Accuray.

2.0

Short Interest

Percentage of Shares Shorted
6.84% of the float of Accuray has been sold short.
Short Interest Ratio / Days to Cover
Accuray has a short interest ratio ("days to cover") of 8.4.
Change versus previous month
Short interest in Accuray has recently decreased by 0.80%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Accuray does not currently pay a dividend.
Dividend Growth
Accuray does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Accuray has received a 72.73% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Radiation therapy machines", "Radiation therapy software", and "Installation services of radiation therapy machines" products. See details.
Environmental Sustainability
The Environmental Impact score for Accuray is -0.77.

2.7

News and Social Media Coverage

News Sentiment
Accuray has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Accuray this week, compared to 2 articles on an average week.
MarketBeat Follows
2 people have added Accuray to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Accuray insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $88,620.00 in company stock.
Percentage Held by Insiders
Only 2.90% of the stock of Accuray is held by insiders.
Percentage Held by Institutions
69.58% of the stock of Accuray is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Accuray are expected to grow in the coming year, from ($0.02) to $0.17 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Accuray is -27.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Accuray is -27.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Accuray has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Accuray (NASDAQ:ARAY) Stock

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

ARAY Price History

30 days | 90 days | 365 days | Advanced Chart

ARAY Stock News Headlines

September 18, 2023 | finance.yahoo.com

Accuray Opens New Global Training Center at Madison, WI Headquarters to Advance Radiotherapy Treatment Techniques Amid Growing Demand for Precision Cancer Care

September 14, 2023 | finance.yahoo.com

Accuray to Host Investor Day at ASTRO on October 3, 2023

October 1, 2023 | Legacy Research (Ad)

Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)

“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”

September 8, 2023 | finance.yahoo.com

Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?

September 5, 2023 | finance.yahoo.com

Accuray Incorporated (NASDAQ:ARAY) is a favorite amongst institutional investors who own 64%

September 1, 2023 | uk.finance.yahoo.com

Accuray Incorporated (ARAY)

August 19, 2023 | seekingalpha.com

Accuray Incorporated - Impressive Growth As Orders Expands

August 11, 2023 | finance.yahoo.com

Loss-Making Accuray Incorporated (NASDAQ:ARAY) Expected To Breakeven In The Medium-Term

October 1, 2023 | Legacy Research (Ad)

Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)

August 10, 2023 | finanznachrichten.de

Accuray Incorporated: Accuray Reports Fourth Quarter and Fiscal 2023 Financial Results

August 10, 2023 | markets.businessinsider.com

Accuray Gets 510(k) Clearance From FDA For VitalHold Breast Package On Radixact System

August 10, 2023 | markets.businessinsider.com

B.Riley Financial Reaffirms Their Buy Rating on Accuray (ARAY)

August 10, 2023 | finance.yahoo.com

Accuray (ARAY) Reports Q4 Earnings: What Key Metrics Have to Say

August 9, 2023 | markets.businessinsider.com

Accuray Incorporated Q4 Loss decreases, but misses estimates

August 9, 2023 | finance.yahoo.com

Accuray Reports Fourth Quarter and Fiscal 2023 Financial Results

August 9, 2023 | finance.yahoo.com

Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market

August 4, 2023 | nasdaq.com

Accuray Incorporated Common Stock (ARAY)

July 27, 2023 | finance.yahoo.com

Accuray to Report Fiscal Year-End 2023 Financial Results on August 9, 2023

July 24, 2023 | money.usnews.com

Accuray Inc

July 23, 2023 | finance.yahoo.com

There's Been No Shortage Of Growth Recently For Accuray's (NASDAQ:ARAY) Returns On Capital

July 13, 2023 | finance.yahoo.com

10 Best Rising Penny Stocks to Buy

June 26, 2023 | finance.yahoo.com

Accuray Incorporated Announces Its Addition to the Russell 2000® Index

June 22, 2023 | msn.com

Cognizant (CTSH) Partners With Accuray to Improve Healthcare

June 21, 2023 | msn.com

Cognizant connects with Accuray for betterment of its radiation therapy business

June 21, 2023 | finance.yahoo.com

Cognizant is Partnering with Accuray to Accelerate Corporate Transformation and Drive Operational Efficiency in Their Radiation Therapy Business

June 15, 2023 | finance.yahoo.com

Accuray Announces Suzanne Winter Selected as One of the Top 50 Healthcare Technology CEOs of 2023

May 23, 2023 | finance.yahoo.com

Investors in Accuray (NASDAQ:ARAY) have seen decent returns of 73% over the past three years

See More Headlines

Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Company Calendar

Last Earnings: 8/09/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:ARAY
CUSIP: 00439710
CIK: 1138723
Web: www.accuray.com
Phone: (408) 716-4600
Fax: 408-716-4601
Employees: 1,024
Year Founded: 1990

Profitability

EPS (Most Recent Fiscal Year): ($0.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,280,000.00
Net Margins: -2.07%
Pretax Margin: -1.52%
Return on Equity: -17.80%
Return on Assets: -1.96%

Debt

Debt-to-Equity Ratio: 3.20
Current Ratio: 1.70
Quick Ratio: 0.97

Sales & Book Value

Annual Sales: $447.61 million
Price / Sales: 0.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.56 per share
Price / Book: 4.86

Miscellaneous

Outstanding Shares: 96,590,000
Free Float: 93,789,000
Market Cap: $262.72 million
Optionable: Optionable
Beta: 1.57

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Ms. Suzanne Winter M.B.A. (Age 60)
Pres, CEO & Director
Comp: $941.01k

Mr. Ali Pervaiz
Sr. VP & CFO

Mr. Michael Hoge
Sr. VP of Global Operations

Mr. Jesse Chew (Age 41)
Sr. VP & Chief Legal Officer
Comp: $645.45k

Ms. Gina Corradetti (Age 49)
VP, Chief Accounting Officer, Principal Accounting Officer & Controller

Mr. GS Jha
Global Chief Information Officer & Chief Information Security Officer

Mr. Patrick R. Spine (Age 52)
Sr. VP & Chief Admin. Officer

Beth Kaplan
PR Director

Ms. Melanie Gebauer
VP of Global HR

Mr. Juki Hozumi
Pres & GM of Japan Region

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARAY Stock - Frequently Asked Questions

How have ARAY shares performed in 2023?: Accuray's stock was trading at $2.09 at the beginning of the year. Since then, ARAY shares have increased by 30.1% and is now trading at $2.72.
View the best growth stocks for 2023 here.
When is Accuray's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ARAY earnings forecast.
How were Accuray's earnings last quarter?: Accuray Incorporated (NASDAQ:ARAY) released its earnings results on Wednesday, August, 9th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.04. The medical equipment provider had revenue of $118.29 million for the quarter, compared to the consensus estimate of $121.50 million. Accuray had a negative net margin of 2.07% and a negative trailing twelve-month return on equity of 17.80%. During the same period in the previous year, the business posted ($0.04) EPS.
What guidance has Accuray issued on next quarter's earnings?: Accuray issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $460.00 million-$470.00 million, compared to the consensus revenue estimate of $451.05 million.
What is Joshua Levine's approval rating as Accuray's CEO?: 107 employees have rated Accuray Chief Executive Officer Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among the company's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 75.0% of employees surveyed would recommend working at Accuray to a friend.
What other stocks do shareholders of Accuray own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?: Accuray trades on the NASDAQ under the ticker symbol "ARAY."
How do I buy shares of Accuray?: Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Accuray's stock price today?: One share of ARAY stock can currently be purchased for approximately $2.72.
How much money does Accuray make?: Accuray (NASDAQ:ARAY) has a market capitalization of $262.72 million and generates $447.61 million in revenue each year. The medical equipment provider earns $-9,280,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.
How many employees does Accuray have?: The company employs 1,024 workers across the globe.
Does Accuray have any subsidiaries?: The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.
Read More
How can I contact Accuray?: Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The official website for the company is www.accuray.com. The medical equipment provider can be reached via phone at (408) 716-4600, via email at mpolyviou@evcgroup.com, or via fax at 408-716-4601.

This page (NASDAQ:ARAY) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial